


PHARMACEUTICAL 2017



AGIOS PHARMACEUTICALS INC. Rank 103 of 313





PHARMACEUTICAL 2017

AGIOS PHARMACEUTICALS INC. Rank 103 of 313



The relative strengths and weaknesses of AGIOS PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AGIOS PHARMACEUTICALS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 152% points. The greatest weakness of AGIOS PHARMACEUTICALS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 105% points.

The company's Economic Capital Ratio, given in the ranking table, is -63%, being 354% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	559,892
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	88,433
Liabilities, Non-Current	0
Other Assets	33,865
Other Compr. Net Income	5.0
Other Expenses	0
Other Liabilities	0
Other Net Income	2,514
Property and Equipment	25,337
Research and Development	220,163
Revenues	69,892
Selling, General and Administrative Expense	50,714

Output Variable	Value in 1000 USD
Assets	619,094
Liabilities	88,433
Expenses	270,877
Stockholders Equity	530,661
Net Income	-198,471
Comprehensive Net Income	-198,468
Economic Capital Ratio	-63%

